Antiseizure medications in children: a quality improvement project

A paper scheduled for online publication on 26 September 2026 in the peer-reviewed journal Epilepsy Research examines how clinicians prescribe antiseizure medications to children who present with acute symptomatic seizures. The work, authored by Maria Gogou, Husna Musa, Jahziel Darisan, Noelle Enright, and Suresh Pujar, adopts a quality improvement methodology — iterative, audit-driven cycles of change rather than a controlled clinical trial — to evaluate routine practice on the ward.

What does the study address?

The project sits within paediatric neurology and clinical pharmacy. It tracks the use of antiseizure medications (drugs that suppress seizure activity, including both older agents such as phenytoin and newer compounds such as levetiracetam) in children whose seizures carry an identifiable acute trigger. Acute symptomatic seizures are provoked events, defined in current classifications as seizures occurring in close temporal relation to a documented systemic, metabolic, toxic, or central nervous system insult — for example, febrile illness, meningitis, electrolyte disturbance, traumatic brain injury, or acute stroke. They differ fundamentally from unprovoked seizures, which by definition recur without an immediate precipitant and form the substrate of epilepsy.

Why does prescribing practice matter in this population?

Because acute symptomatic seizures have a defined cause, management centres on treating that cause rather than committing the child to long-term anticonvulsant therapy. Practice nonetheless varies across centres, and inappropriate continuation of antiseizure medications beyond the acute phase exposes children to drug-related adverse effects — sedation, behavioural change, hepatic and haematological monitoring — without commensurate benefit. The paper's quality improvement framing signals that the authors audited existing prescribing behaviour against an agreed local standard, measured deviation from that standard, implemented a corrective intervention, and re-measured adherence, typically through several Plan-Do-Study-Act cycles (small, repeated tests of change that allow teams to refine an intervention between measurement points).

What does the quality improvement framework add?

Quality improvement methodology, moved from industrial process engineering into healthcare from the early 2000s onward, prioritises measurable change in a specific care process over generalisable biological inference. In paediatric prescribing, that framing shifts attention from whether a given antiseizure medication works — a question for randomised controlled trials — to whether the right children receive the right drug for the right duration at the bedside. The five-author team, led clinically by Maria Gogou and Suresh Pujar, places its work in this operational tradition, where the unit of analysis is the prescription chart and the outcome of interest is adherence to a documented standard of care.

How does the work sit in the broader evidence base?

Acute symptomatic seizures account for a substantial proportion of paediatric seizure presentations to emergency departments, particularly in infants and preschool children, where febrile and infectious triggers predominate. National and international guidelines already recommend restricting antiseizure medications to the acute phase unless specific risk markers — status epilepticus, structural lesions, or prolonged acute encephalitis, for instance — indicate otherwise. The forthcoming Epilepsy Research paper enters this space as a practice-level audit rather than a guideline revision, and its value to readers will rest on the size of the cohort, the clarity of the prescribing standard chosen, and the durability of any improvement demonstrated after the intervention.

What should monitoring units and reading rooms expect?

Readers should expect the full text, available from 26 September 2026, to specify the institutional setting, the baseline audit cycle, the intervention deployed, and the post-intervention prescribing rates. Until the methods and results sections are in hand, the headline contribution is methodological: a structured attempt to translate guidance on acute symptomatic seizure management into measurable behaviour at the prescribing interface. For paediatric wards and on-call pharmacists, such projects typically yield concrete change ideas — order-set modifications, documentation prompts, and structured deprescribing checklists — rather than new diagnostic categories or imaging protocols.

As the full text becomes available later this month, clinical teams running paediatric acute neurology services will be able to benchmark their own prescribing patterns against the project's audit criteria and, where appropriate, adapt the change package to local workflows.